

Helmuth Reuter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9418025/publications.pdf>

Version: 2024-02-01

20
papers

283
citations

1307594

7
h-index

996975

15
g-index

20
all docs

20
docs citations

20
times ranked

490
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug concentration at the site of disease in children with pulmonary tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1710-1719.	3.0	3
2	A retrospective review of calls to the Poisons Information Helpline of the Western Cape during the first 6 months of the COVID-19 pandemic in South Africa. <i>Southern African Journal of Infectious Diseases</i> , 2022, 37, 391.	0.5	4
3	Therapeutic Benefit in Rheumatoid Cachexia Illustrated Using a Novel Primary Human Triple Cell Coculture Model. <i>International Journal of Inflammation</i> , 2022, 2022, 1-14.	1.5	1
4	Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 2010-2021.	1.9	11
5	Outcome of clinical and subclinical myocardial injury in systemic lupus erythematosus – A prospective cohort study. <i>Lupus</i> , 2021, 30, 256-268.	1.6	10
6	Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. <i>PLoS ONE</i> , 2021, 16, e0247852.	2.5	45
7	The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 637618.	3.5	4
8	Pharmacokinetics of Para-aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 489-494.	2.0	3
9	Myocardial injury in systemic lupus erythematosus according to cardiac magnetic resonance tissue characterization: clinical and echocardiographic features. <i>Lupus</i> , 2020, 29, 1461-1468.	1.6	5
10	Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018. <i>BMC Infectious Diseases</i> , 2020, 20, 900.	2.9	4
11	The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2123-2132.	2.4	14
12	Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1557-1565.	1.9	2
13	Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1103-1129.	3.5	50
14	Critical evaluation of causality assessment of herb-drug interactions in patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 679-693.	2.4	101
15	Speckle tracking echocardiography in acute lupus myocarditis: comparison to conventional echocardiography. <i>Echo Research and Practice</i> , 2017, 4, 9-19.	2.5	14
16	Talking rural in Beaufort-West. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2007, 49, 54-55.	0.6	0
17	Editorial comment for updAIDS column. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2007, 49, 35-35.	0.6	3
18	updAIDS in SA Family Practice. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2006, 48, 55-57.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Experience with adjunctive corticosteroids in managing tuberculous pericarditis. , 2006, 17, 233-8.		5
20	Adenosine deaminase activity--more than a diagnostic tool in tuberculous pericarditis. , 2005, 16, 143-7.		4